Skip to main content
Jennison Associates logoJennison Associates logo
  • About Us
  • Equity

    • Large Cap Growth
    • Global
    • International
    • Emerging Markets
    • Mid Cap Growth
    • Small Cap Core

    Equity

    • SMid Cap Core
    • Large Cap Value
    • Global Equity Income
    • Rising Dividend

    Thematic Equity

    • Health Sciences
    • Utility Equity
    • Global Infrastructure
    • Global Natural Resources
    • MLP (Master Limited Partnerships)
    • Financial Services

    Thematic Equity

    • Technology Equity
  • Fixed Income
    • Active Long Duration
    • Active Core
    • Active Intermediate
    • Stable Value
    • LDI
  • ESG Overview
    • Integration
    • Proxy Voting
    • Engagement
    • Corporate Citizenship
  • Perspectives
  • Contact Us
jennison swoosh_1290x842.jpg
Article

Healthcare Opportunities in 2023 and BeyondHealthcareOpportunitiesin2023andBeyond

By Daniel Matviyenko & Debra Netschert — May 22, 2023

Share
  • Mail
  • LinkedIn
  • Twitter
  • Copy URL

Share

The healthcare sector is one of dynamism, where global demographic trends, breakthrough drug developments, and merger and acquisition (M&A) activity can offer diverse sources of alpha. Historically, the sector has provided access to secular long-term growth and has outperformed broader market indexes, including the S&P 500 and Nasdaq, over full market cycles since the late 1990s (Exhibit 1). 

Innovation is modernizing the industry, as technology adoption is improving the patient experience and contributing to lower costs. Patients have become more tech savvy and more aware of their own health. At the same time, advancements in the ability to diagnose, monitor, and treat diseases with personalized therapeutics is creating a broad set of investment opportunities.

We believe the current wave of consumerization and innovation is paving the way for a select group of healthcare companies with access to data to generate durable, outsized growth over the next decade. In our view, moves to replace legacy approaches and provide more impactful and efficient care should parallel the evolution of the information technology sector from 2010 to 2020.

Recent Biotech Drawdowns Mirror Technology’s “Dotcom” Era

Similar to technology’s dotcom crash that preceded the sector’s decade-long run of outsized growth, the healthcare sector has experienced recent volatility. The drawdowns in early stage therapeutics are similar to the drawdowns of less mature technology companies in the early 2000s. Performance of the biotech sector resembles that of the technology sector after the 1999 bull market, when it took nearly two years for the Nasdaq to find its footing following the 2000 crash. Exhibit 2 overlays the past three years of performance for the S&P Biotechnology Select Industry Index (2020-2022) relative to the Nasdaq results (1999-2002). As shown below, the historical return patterns closely match, with an approximate 0.9 correlation coefficient.

  

A Handful of Winners Could Emerge from Recent Volatility

While the technology sector ultimately recovered from the dotcom crash, the recovery was not uniform. Currently, there are a handful of large technology conglomerates with entrenched competitive advantages. Over the long term, we believe the biotech recovery will follow a similar pattern and expect companies with the best science to lead the way, while others simply disappear.

In the near term, though we continue to be bullish on the outlook for select companies in the biotech and therapeutics sub-sectors, our view in aggregate is nuanced and we expect that alpha generation derived from bottom-up stock selection will be paramount. We believe too much public company creation over the past five years fostered an environment where “less-than-ready" companies were vying for capital, thus overly diluting the pool of investible ideas. Mid-cap biotech has been a more interesting source of long ideas for our team, as many of these companies have pipelines and also offer positive EBITDA. These attributes make them more attractive in a rising rate environment and, more importantly, attractive to larger potential "suitors."  

Data should also play a crucial function in defining long-term winners in the healthcare sector. Tech-enabled healthcare is the future of the industry and data enables the development of methods to monitor and optimize the delivery of care and also allows physicians to better understand patients. Over time, we expect the healthcare companies that can effectively collect, process, and interpret data to emerge as the industry’s large conglomerates with established competitive advantages.

The Benefits of Long/Short Active Management

Healthcare’s combination of innovation and performance dispersion among individual companies make it a compelling space for skilled active managers to identify attractive long and short positions.

On the innovation front, advances in DNA sequencing, artificial intelligence, and computational biology in the biotech industry have translated into new treatments for chronic diseases such as diabetes and obesity. There are also early signs that more effective obesity treatments are having a positive impact on cardiovascular disease, which is among the world’s deadliest and most costly conditions to treat. For investors, these advancements are creating new opportunities among select pharmaceutical companies that have the depth of resources—including large balance sheets and workforce—to capitalize on this enormous market for cardiovascular treatments and disease prevention.

At the same time, we also expect the biotech industry to remain volatile. Against this backdrop, we believe that experienced long/short managers will have significant opportunities to generate alpha.

Innovation in the sector expands beyond biotech and biopharma companies. For example, a shift towards a value-based care model where costs are directly associated with the quality of the result is encouraging technology investments to increase efficiencies. Healthcare service providers are guiding this evolution through access to patient data and developing methods to monitor and optimize the delivery of care. Additionally, the forward opportunity for medical equipment appears to be improving as reduced concerns about inflation, nurse shortages, the strong dollar, and hospital spending reduce the backlog for surgical procedures. We believe this should provide above historic trend growth for well positioned companies. 

In our view, exposure to the healthcare sector can diversify a strategic asset allocation. As we look ahead, we believe the sector can continue to outperform over the long term, as investors place more emphasis on stable company fundamentals and the significant alpha-generation that broad innovation can provide.

Contact Us
Jennison Associates

Jennison's investing approach is rooted in our fundamental research and security selection; all of our portfolios are built from the bottom-up, security by security.

Contact Us

  • By Daniel MatviyenkoManaging Director, Jennison Associates
  • By Debra NetschertManaging Director, Jennison Associates

A short sale creates the risk of a theoretically unlimited loss. Investing in the health care sector increases vulnerability to economic, political, or regulatory developments affecting this sector. The share prices of health care companies can drop dramatically. Investing in small-and mid-cap stocks may be subject to more erratic market movements and liquidity constraints than large-cap stocks.

The financial indexes referenced herein are provided for informational purposes only. All indexes referenced are registered trade names or trademark/ service marks of third parties. References to such trade names or trademark/service marks and data are proprietary and confidential and cannot be redistributed without Jennison's prior consent. Investors cannot directly invest in an index.

The S&P index(es) (“Index”) is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Jennison Associates, LLC. Copyright © 2021 S&P Dow Jones Indices LLC, a division of S&P Global, Inc., and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC. For more information on any of S&P Dow Jones Indices LLC’s indices please visit www.spdji.com. S&P® is a registered trademark of S&P Global and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC.

The Nasdaq Index is a basket of the 100 largest, most actively traded U.S companies listed on the Nasdaq stock exchange. The index includes companies from various industries except for the financial industry, like commercial and investment banks. These non-financial sectors include retail, biotechnology, industrial, technology, health care, and others.

  • About Us

    • About Jennison
    • Firm Profile
    • Our Approach to Investing
    • Contact Us - Form
  • Other Resources

    • Form CRS
Jennison Associates logo
  • Terms & Conditions
  • PGIM Privacy Center
  • Accessibility Help
  • Cookie Preference Center

Jennison Associates LLC. All Rights Reserved.

This website is intended for Institutional and Professional Investors only. All investments involve risk, including the possible loss of capital.

Important Disclosures

Jennison Associates is a registered investment advisor under the U.S. Investment Advisers Act of 1940, as amended, and a Prudential Financial, Inc. (“PFI”) company. Registration as a registered investment adviser does not imply a certain level or skill or training.  Jennison Associates LLC has not been licensed or registered to provide investment services in any jurisdiction outside the United States. Certain investment vehicles are distributed or offered through Prudential Investment Management Services LLC (also a Prudential Financial, Inc. (“PFI”) company) or other affiliated entities. Additionally, vehicles may not be registered or available for investment in all jurisdictions. Prudential Financial, Inc. of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. 

Please visit https://www.jennison.com/important-disclosuresopens in a new window for important information, including information on non-US jurisdictions 

This web site is not intended as an offer or solicitation with respect to the purchase or sale of any security or other financial instrument or any investment management services. It does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. This is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence.

Any views or opinions expressed on this website reflect the opinions of Jennison investment professionals at the time they are made and are subject to change.

Your investment objectives, risk tolerance, and liquidity needs must be reviewed before suitable programs can be recommended. Asset allocation and diversification strategies do not assure a profit or protect against loss in declining markets. Investors should consult with their attorney, accountant, and/or tax professional for advice concerning their particular situation.

Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that the investment managers’ objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors.

There is no guarantee our objectives will be met. All investments contain risk, including possible loss of principal. The strategy may vary significantly from the benchmark in several ways including, but not limited to, sector and issuer weightings, portfolio characteristics, and security types.

Information for persons in the United Kingdom and various European Economic Area jurisdictions
In the United Kingdom, information is issued by PGIM Limited with registered office: Grand Buildings, 1-3 Strand, Trafalgar Square, London, WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number 193418). In the European Economic Area (“EEA”), information is issued by PGIM Netherlands B.V. with registered office: Gustav Mahlerlaan 1212, 1081 LA  Amsterdam, The Netherlands. PGIM Netherlands B.V. is authorised by the Autoriteit Financiële Markten (“AFM”) in the Netherlands (Registration number 15003620) and operating on the basis of a European passport. In certain EEA countries, information is, where permitted, presented by PGIM Limited in reliance of provisions, exemptions or licenses available to PGIM Limited under temporary permission arrangements following the exit of the United Kingdom from the European Union. Jennison Associates LLC, PGIM Limited & PGIM Netherlands B.V. are wholly owned subsidiaries of PGIM, Inc. the principal investment management business of Prudential Financial, Inc. (‘PFI’).  PFI of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. These materials are issued by PGIM Limited and/or PGIM Netherlands B.V. to persons who are professional clients as defined  under the rules of the FCA and/or to persons who are professional clients as defined in the relevant local implementation of Directive 2014/65/EU (MiFID II).

Links to third-party sites are intended for informational purposes only and should not be considered investment advice or recommendation to invest. These links do not constitute endorsement or confirm their accuracy, and we are not responsible for any third-party guidelines, security, or accuracy of information.

You are viewing this page in preview mode.

Edit Page